Optic neuropathy in patients with glioblastoma receiving bevacizumab.
Chamberlain
Marc C
MC
Raizer
Jeffrey
J
Schiff
David
D
Sherman
Jonathan H
JH
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000150:complications / Q000188:drug therapy*; D005909:Glioblastoma / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D009901:Optic Nerve Diseases / Q000150:complications / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab